HCW Biologics Inc (HCWB)vsRoyalty Pharma Plc (RPRX)
HCWB
HCW Biologics Inc
$1.79
-13.53%
HEALTHCARE · Cap: $11.67M
RPRX
Royalty Pharma Plc
$55.02
-0.76%
HEALTHCARE · Cap: $31.60B
Smart Verdict
WallStSmart Research — data-driven comparison
Royalty Pharma Plc generates 36921% more annual revenue ($2.44B vs $6.59M). RPRX leads profitability with a 33.9% profit margin vs -34.7%. RPRX earns a higher WallStSmart Score of 65/100 (C+).
HCWB
Hold43
out of 100
Grade: D
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HCWB.
Margin of Safety
-59.6%
Fair Value
$34.38
Current Price
$55.02
$20.64 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 49.4%
Revenue surging 129081.0% year-over-year
Reasonable price relative to book value
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : HCWB
The strongest argument for HCWB centers on Operating Margin, Revenue Growth, Price/Book. Revenue growth of 129081.0% demonstrates continued momentum.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : HCWB
The primary concerns for HCWB are EPS Growth, Market Cap, Debt/Equity.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
HCWB profiles as a hypergrowth stock while RPRX is a mature play — different risk/reward profiles.
HCWB carries more volatility with a beta of 1.14 — expect wider price swings.
HCWB is growing revenue faster at 129081.0% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (65/100 vs 43/100), backed by strong 33.9% margins and 11.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
HCW Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
HCW Biologics Inc is a pioneering biotechnology firm focused on advancing immunotherapies and vaccine technologies to tackle critical health issues like cancer and infectious diseases. By utilizing proprietary platforms designed to optimize immune response, the company is developing a promising pipeline of clinical candidates that aim to revolutionize patient treatment. With strategic partnerships and a dedication to fulfilling unmet medical needs, HCW Biologics stands at the forefront of the biotechnology industry, representing a compelling investment opportunity amid the sector's growth.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?